Forteo

(Teriparatide)

ApprovedPeptide

Teriparatide is used to treat osteoporosis (weak bones) by stimulating bone formation and increasing bone density, helping to reduce the risk of fractures.[2] Forteo is currently approved and in use across 17 indications[4].[1]

Forteo is one of 230 small molecule programs targeting Osteopenia. It is currently in Approved.

Indications

121

Total Trials

Active Trials

229

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

OsteopeniaApproved

Hip FractureCompleted

Bone FractureActive, not recruiting

Neurogenic ArthropathyApproved

Humerus FractureApproved

Spinal FusionCompleted

Postmenopausal OsteoporosisCompleted

Secondary HyperparathyroidismActive, not recruiting

Osteogenesis ImperfectaCompleted

Rheumatoid ArthritisCompleted

OsteopeniaApproved

Approved

Hip FractureApproved

Completed

Bone FractureApproved

Active, not recruiting

Neurogenic ArthropathyApproved

Approved

Humerus FractureApproved

Approved

Spinal FusionApproved

Completed

Postmenopausal OsteoporosisApproved

Completed

Secondary HyperparathyroidismPreclinical

Active, not recruiting

Osteogenesis ImperfectaApproved

Completed

Rheumatoid ArthritisApproved

Completed

Showing 10 of 17 indications

Competition

Competitive Landscape

176 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Forteo

AAlmaject

Approved

1 2

Actos

Takeda

Preclinical

2 3

Celexa

AbbVie

Preclinical

1 4

Voltaren

Cataflam

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 8

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Nsaids

Roche

Preclinical

1 10

Disalcid

JJoslin Diabetes Center

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Osteoporosis

NCT06898060

Q3 2027

Post-ApprovalRecruiting

Chronic Kidney Disease

NCT04522622

Q4 2027

ApprovedRecruiting

Osteoporosis, Postmenopausal

NCT06558188

Recruiting

Osteoporosis, Postmenopausal

NCT06164795

Q4 2030

Active, not recruiting

Treatment

NCT03692143

Clinical

Trials by Indication[1]

Osteoporosis39 trials

Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT01166958·26 enrolled

Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00670501·1,637 enrolled

Precision Medicine Approach for Osteoporosis - Follow Up Study

Enrolling by invitation·PPaul F Netzel·Phase 4·NCT06264609·40 enrolled

Show 36 more trials

Back Pain in Patients With Severe Osteoporosis

Completed· Eli Lilly logo

Eli Lilly··NCT00761332·650 enrolled

A Study of the Treatment of Postmenopausal Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00543023·104 enrolled

Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00542984·70 enrolled

Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women

Completed·EElizabeth Shane·Phase 2·NCT01440803·41 enrolled

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00035256·330 enrolled

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00051558·428 enrolled

Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis

Completed·ZZosano Pharma Corporation·Phase 2·NCT00489918·165 enrolled

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Completed· Novartis logo

Novartis·Phase 3·NCT00439244·412 enrolled

Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis

Completed·—·Phase 3·NCT01611571·31 enrolled

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00079924·200 enrolled

A Study for Teriparatide in Severe Osteoporosis

Completed· Eli Lilly logo

Eli Lilly··NCT00696644·794 enrolled

Teriparatide Treatment in Patients With Inherited Osteoporosis

Completed·HHelsinki University Central Hospital·Phase 4·NCT01360424·6 enrolled

Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication

Completed·—··NCT02472782·851 enrolled

Replication of the VERO Osteoporosis Trial in Healthcare Claims Data

Completed·—··NCT04879420·12,757 enrolled

Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis

Unknown status·UUniversity Health Network, Toronto··NCT01155232·100 enrolled

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

Terminated· GSK logo

GSK·Phase 2·NCT00471237·564 enrolled

Stem Cell Recruitment in Osteoporosis Therapy

Terminated·JJohns Hopkins University·N/A·NCT01656629·55 enrolled

Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00503399·92 enrolled

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00343252·712 enrolled

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00046137

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

Recruiting·MMadhumathi Rao·Phase 4·NCT05151484·60 enrolled

A Study for Patients With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00414973·364 enrolled

Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00577863·200 enrolled

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis

Completed·—·Phase 2·NCT00005006·140 enrolled

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

Completed·RRadius Health, Inc.·Phase 2·NCT00542425·222 enrolled

Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT01753856·69 enrolled

Once Weekly Parathyroid Hormone for Osteoporosis

Completed·UUniversity of California, San Francisco·Phase 3·NCT00065637·50 enrolled

A Comparison of PF708 and Forteo in Osteoporosis Patients

Completed·PPfenex, Inc·Phase 3·NCT03002428·181 enrolled

To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT06898060·282 enrolled

Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women

Completed·—·Phase 2/3·NCT00697463·22 enrolled

Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00532207·50 enrolled

Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00259298·12 enrolled

A Study of Teriparatide in Japanese Osteoporosis Patients

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT01430104·30 enrolled

Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis

Completed·TTransPharma Medical·Phase 2·NCT00535860·104 enrolled

PTH and Vibration in OSteoporosis Study

Completed·OOdense University Hospital·N/A·NCT02563353·35 enrolled

Determination of Selective Bone Turnover Markers and Their Association With Treatment Efficacy in Primary Postmenopausal Osteoporotic Women: A Randomized Control Trial

Completed·KKhyber Medical University Peshawar·Preclinical·NCT07242612·40 enrolled

Postmenopausal Osteoporosis7 trials

µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis

Completed·UUniversity of Pennsylvania·Phase 4·NCT01153425·33 enrolled

Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00532545·45 enrolled

MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis

Completed·MMedical University of Vienna·Phase 4·NCT03472846·26 enrolled

Show 4 more trials

Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis

Completed·MMedical University of Vienna·Phase 4·NCT01535027·125 enrolled

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

Completed·MMassachusetts General Hospital·Phase 2·NCT00926380·94 enrolled

2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00191425·810 enrolled

Weekly vs Daily Teriparatide Therapy in Severe Postmenopausal Osteoporosis

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT01760798·20 enrolled

Treatment6 trials

VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT01709110·1,366 enrolled

Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP

Active, not recruiting·NNanfang Hospital, Southern Medical University··NCT03692143·90 enrolled

Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo

Suspended·MMedical University of Vienna·Phase 4·NCT01734824·90 enrolled

Show 3 more trials

A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00557310·35 enrolled

The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures

Unknown status·OOhio Orthopedic Center of Excellence·Phase 4·NCT01173081·38 enrolled

Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00927186·69 enrolled

Postmenopausal Women6 trials

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Completed·RRadius Health, Inc.··NCT04974723·22,054 enrolled

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Completed·RRadius Health, Inc.·Phase 3·NCT01343004·2,463 enrolled

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

Completed· Amgen logo

Amgen·Phase 3·NCT01796301·436 enrolled

Show 3 more trials

Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass

Unknown status·AAzelon Pharmaceuticals·Phase 2·NCT01604057·130 enrolled

Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD

Withdrawn·NNastech Pharmaceutical Company, Inc.·Phase 2·NCT00624481·350 enrolled

Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action

Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 4·NCT01293292·19 enrolled

Fracture6 trials

Study of Teriparatide in Stress Fracture Healing

Unknown status·UUniversity of East Anglia·Phase 3·NCT04196855·136 enrolled

Fracture Recovery for Returning to Duty (Teriparatide STRONG)

Enrolling by invitation·UUniversity of South Carolina·Phase 4·NCT04589819·183 enrolled

Use of Teriparatide to Accelerate Fracture Healing

Terminated·UUniversity of Rochester·N/A·NCT00594906·10 enrolled

Show 3 more trials

The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA

Completed·KKing Chulalongkorn Memorial Hospital·Phase 3·NCT03133195·50 enrolled

Teriparatide for Fracture Repair in Humans

Withdrawn·MMedical University of Vienna·Phase 3·NCT02091492

Fracture (FX) Improvement With Teriparatide: FiX-IT Study

Completed·SSusan L. Greenspan·Phase 4·NCT01705587·13 enrolled

37 more indications

Spinal Cord Injury3 trials

12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)

Completed·NNorthwestern University·Phase 2·NCT02025179·25 enrolled

Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)

Completed·—·Phase 4·NCT00826228·12 enrolled

Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury

Completed·—·Phase 2·NCT01225055·60 enrolled

Bone3 trials

Bone Effects of Teriparatide Following Alendronate

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191893·66 enrolled

Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration

Completed·MMassachusetts General Hospital·Phase 4·NCT04026256·37 enrolled

Cyclic Versus Daily Teriparatide on Bone Mass

Unknown status·—·Phase 2·NCT00668941·140 enrolled

Hip Fracture3 trials

Effect of Teriparatide on Hip Fracture Healing

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01473589·122 enrolled

Second Study of the Effect of Teriparatide on Hip Fracture Healing

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01473602·39 enrolled

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00887354·224 enrolled

Low Bone Mineral Density2 trials

Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

Completed· Amgen logo

Amgen·Phase 2·NCT00896532·419 enrolled

The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density

Terminated·PPapageorgiou General Hospital·Phase 4·NCT00446589·19 enrolled

Trial2 trials

Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00239629·73 enrolled

The Forteo Alendronate Comparator Trial

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT02416271·203 enrolled

Thyroid2 trials

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

Terminated·UUniversity of Michigan·Phase 2·NCT01279187·27 enrolled

Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur

Completed·HHealth Research, Inc.·N/A·NCT01309399·40 enrolled

Clinical Trial2 trials

Phase 3 Clinical Trial of Teriparatide in Japan

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00433160·207 enrolled

Clinical Trial of Teriparatide in Japan

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191867·160 enrolled

Oral2 trials

A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects

Completed·EEntera Bio Ltd.·Phase 1·NCT02202603·42 enrolled

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects

Completed·EEntera Bio Ltd.·Phase 1·NCT02571140·30 enrolled

Hypoparathyroidism2 trials

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02824718·16 enrolled

Teriparatide for Postsurgical Hypoparathyroidism

Terminated·MMayo Clinic·Phase 2·NCT01171690·5 enrolled

Hypocalcemia2 trials

Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).

Completed·SSaint Petersburg State University, Russia·Phase 3·NCT04750460·20 enrolled

Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00623974·7 enrolled

Osteogenesis Imperfecta2 trials

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

Completed·OOregon Health and Science University·Phase 4·NCT00131469·79 enrolled

The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta

Terminated·UUniversity of Aarhus·Phase 2·NCT01679080·9 enrolled

Osteoporosis, Postmenopausal2 trials

Combined Anabolic Therapy Study

Recruiting·MMassachusetts General Hospital·Approved·NCT06558188·50 enrolled

Efficacy of Sequential Therapies After Osteoanabolic Treatment in Postmenopausal Women With Severe Osteoporosis: the Sequential Treatment After Romosozumab and Teriparatide/Abaloparatide (START) Study

Recruiting·4424 General Military Hospital··NCT06164795·150 enrolled

ESS1 trial

A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo

Completed·GGedeon Richter Plc.·Phase 1·NCT02223416

Anorexia Nervosa1 trial

The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa

Completed·MMassachusetts General Hospital·Phase 2·NCT00759772·23 enrolled

Spine Fusion1 trial

Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion

Completed·SShane Burch·Phase 4·NCT01292252·36 enrolled

Menopausal Women1 trial

PTH Comparison in Post Menopausal Women

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00543218·63 enrolled

MPR1 trial

Teriparatide for Improved Knee Prosthesis Fixation

Completed·UUniversity Hospital, Linkoeping·Phase 2·NCT01063504·60 enrolled

MPA1 trial

A Comparison Study of PF708 and Forteo in Healthy Subjects

Completed·PPfenex, Inc·Phase 1·NCT02656810·70 enrolled

Fractures1 trial

Does Teriparatide (rhPTH 1-34) Promote Fracture Healing in Proximal Humeral Fractures?

Completed·UUniversity Hospital, Linkoeping·Phase 4·NCT01105832·40 enrolled

Vertebral Compression Fracture1 trial

Efficacy of WJ-derived Mesenchymal Stem Cells in Combination With Parathyroid Hormone for Vertebral Compression Fracture

Unknown status·IInbo Han·Phase 2·NCT05018637·30 enrolled

Rheumatoid Arthritis1 trial

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

Completed·—·Phase 4·NCT01400516·26 enrolled

Radius Fracture1 trial

Effects of Teriparatide on Distal Radius Fracture Healing

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00190944·105 enrolled

Osteocalcin1 trial

Effect of Vitamin K Supplementation on Circulating Levels of Osteocalcin on the Bone Metabolism and Aging

Terminated·UUniversity of Milano Bicocca·N/A·NCT04669782·99 enrolled

Metabolism1 trial

Circulating Myokine Levels and Bone Metabolism

Completed·—··NCT04206618·220 enrolled

Osseointegration1 trial

Teriparatide on Maxillary Sinus Floor Osseointegration

Unknown status·UUniversidad de Valparaiso·Phase 4·NCT06061354·42 enrolled

Arthropathy1 trial

Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot

Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2·NCT02023411·20 enrolled

Femur Fracture1 trial

Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures

Completed·UUniversity Health Network, Toronto·Phase 3·NCT01896011·34 enrolled

Renal Osteodystrophy1 trial

Renal Osteodystrophy: An Individual Management Approach

Completed·—·N/A·NCT02440581·141 enrolled

Sex1 trial

Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes

Completed·—·Phase 3·NCT04921124·30 enrolled

Spinal Fusion1 trial

Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?

Completed·UUniversity Hospital, Linkoeping·Phase 4·NCT02090244·34 enrolled

Secondary Hyperparathyroidism1 trial

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

Completed·UUniversity of Maryland, Baltimore·N/A·NCT00754442·20 enrolled

Efficacy and Safety1 trial

Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo

Unknown status·BBio Sidus SA·Phase 4·NCT01945788·110 enrolled

Chronic Kidney Disease1 trial

Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease

Recruiting·DDitte Hansen·Phase 4·NCT04522622·48 enrolled

Lumbar Fusion Surgery1 trial

Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery

Recruiting·TThe University of Hong Kong·N/A·NCT03770338·192 enrolled

Prevention1 trial

Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture

Recruiting·PPeking Union Medical College Hospital·N/A·NCT05866029·2,478 enrolled

Lower Extremity Fracture1 trial

PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures

Not yet recruiting·UUniversity of Calgary·Preclinical·NCT06303284·54 enrolled

Unspecified6 trials

Teriparatide Use in Hip Replaced Subjects

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191321·60 enrolled

Teriparatide as a Chondroregenerative Therapy in OA

Completed·CChristopher Ritchlin·Phase 2·NCT03072147·76 enrolled

Denosumab and Teriparatide Study (DATA-HD and DATA-EX)

Completed·MMassachusetts General Hospital·Phase 4·NCT02176382·76 enrolled

Show 3 more trials

The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL

Withdrawn·—·N/A·NCT00347737

A Study for the Transdermal Application of Teriparatide

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01011556·233 enrolled

Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191802·120 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 23, 1987

PARATHAR

NDA NDA019498

Nov 26, 2002

FORTEO

NDA NDA021318

Jun 2, 2004

FORTEO

NDA NDA021318

Sep 3, 2004

FORTEO

NDA NDA021318

May 19, 2007

FORTEO

NDA NDA021318

Feb 28, 2008

FORTEO

NDA NDA021318

Jun 25, 2008

FORTEO

NDA NDA021318

Jun 25, 2008

FORTEO

NDA NDA021318

Jul 22, 2009

FORTEO

NDA NDA021318

Aug 10, 2011

FORTEO

NDA NDA021318

Mar 13, 2012

FORTEO

NDA NDA021318

Feb 15, 2013

FORTEO

NDA NDA021318

Mar 13, 2013

FORTEO

NDA NDA021318

Aug 2, 2013

FORTEO

NDA NDA021318

Aug 30, 2013

FORTEO

NDA NDA021318

Jan 24, 2014

FORTEO

NDA NDA021318

Mar 5, 2014

FORTEO

NDA NDA021318

Apr 11, 2014

FORTEO

NDA NDA021318

Aug 13, 2014

FORTEO

NDA NDA021318

Sep 12, 2014

FORTEO

NDA NDA021318

Nov 23, 2015

FORTEO

NDA NDA021318

Apr 28, 2017

FORTEO

NDA NDA021318

Oct 3, 2019

FORTEO

NDA NDA021318

Oct 4, 2019

BONSITY

NDA NDA211939

Apr 6, 2020

FORTEO

NDA NDA021318

Nov 16, 2020

FORTEO

NDA NDA021318

Sep 7, 2021

FORTEO

NDA NDA021318

Jun 4, 2024

TERIPARATIDE

NDA NDA218771

Jul 24, 2024

FORTEO

NDA NDA021318

Aug 3, 2026

FORTEO

NDA NDA021318

Sources

References

[1]
ClinicalTrials.gov — 121 trial records for Teriparatide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Forteo drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Teriparatide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Teriparatide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021318). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Almaject company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Parathyroid Hormone Receptor Agonist[3]
Modality: Peptide[3]
Highest Phase: Approved[1]
Company: AAlmaject

Forteo

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Q4 2030

Trials by Indication[1]

Osteoporosis39 trials

Postmenopausal Osteoporosis7 trials

Treatment6 trials

Postmenopausal Women6 trials

Fracture6 trials

Spinal Cord Injury3 trials

Bone3 trials

Hip Fracture3 trials

Low Bone Mineral Density2 trials

Trial2 trials

Thyroid2 trials

Clinical Trial2 trials

Oral2 trials

Hypoparathyroidism2 trials

Hypocalcemia2 trials

Osteogenesis Imperfecta2 trials

Osteoporosis, Postmenopausal2 trials

ESS1 trial

Anorexia Nervosa1 trial

Spine Fusion1 trial

Menopausal Women1 trial

MPR1 trial

MPA1 trial

Fractures1 trial

Vertebral Compression Fracture1 trial

Rheumatoid Arthritis1 trial

Radius Fracture1 trial

Osteocalcin1 trial

Metabolism1 trial

Osseointegration1 trial

Arthropathy1 trial

Femur Fracture1 trial

Renal Osteodystrophy1 trial

Sex1 trial

Spinal Fusion1 trial

Secondary Hyperparathyroidism1 trial

Efficacy and Safety1 trial

Chronic Kidney Disease1 trial

Lumbar Fusion Surgery1 trial

Prevention1 trial

Lower Extremity Fracture1 trial

Unspecified6 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News